Send to

Choose Destination
Oncoimmunology. 2012 Sep 1;1(6):997-999.

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.

Author information

Melanoma Institute Australia; Sydney, NSW Australia ; University of Sydney; Sydney, NSW Australia.


Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center